News CorMedix Inc.

Stocks

CRMD

US21900C3088

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 08:44:53 17/07/2026 pm IST			5-day change	1st Jan Change
8.355 ^USD	+0.78%		0.00%	-27.77%

07/07	RBC Capital Trims CorMedix Price Target to $13 From $14, Maintains Outperform Rating	MT
03/07	CorMedix Names Elizabeth Hurlburt as Chief Operating, Commercial Officer	MT

All News

Mentions Relevance

07/07	RBC Capital Trims CorMedix Price Target to $13 From $14, Maintains Outperform Rating	MT
03/07	CorMedix Names Elizabeth Hurlburt as Chief Operating, Commercial Officer	MT
03/07	Cormedix Inc. Announces Executive Changes	CI
30/06	CorMedix Inc.(NasdaqGM:CRMD) dropped from Russell Small Cap Comp Growth Benchmark	CI
30/06	CorMedix Inc.(NasdaqGM:CRMD) dropped from Russell 2500 Growth Benchmark	CI
29/06	CorMedix Inc.(NasdaqGM:CRMD) added to Russell 2000 Value Benchmark	CI
29/06	CorMedix Inc.(NasdaqGM:CRMD) added to Russell Microcap Value Benchmark Index	CI
29/06	CorMedix Inc.(NasdaqGM:CRMD) dropped from Russell 2000 Growth Benchmark	CI
29/06	CorMedix Inc.(NasdaqGM:CRMD) dropped from Russell 3000E Growth Benchmark	CI
29/06	CorMedix Inc.(NasdaqGM:CRMD) added to Russell 3000E Value Benchmark	CI
29/06	CorMedix Inc.(NasdaqGM:CRMD) dropped from Russell Microcap Growth Benchmark Index	CI
29/06	CorMedix Inc.(NasdaqGM:CRMD) added to Russell 3000 Value Benchmark	CI
29/06	CorMedix Inc.(NasdaqGM:CRMD) dropped from Russell 3000 Growth Benchmark	CI
29/06	CorMedix Inc.(NasdaqGM:CRMD) added to Russell Small Cap Comp Value Benchmark	CI
29/06	CorMedix Inc.(NasdaqGM:CRMD) added to Russell 2500 Value Benchmark	CI
08/06	U.S. Court of Appeals for the Federal Circuit Affirms Victory for Cormedix Therapeutics in Minocin® Patent Litigation	AQ
15/05	Cormedix Therapeutics to Participate in two Upcoming Investor Conferences	AQ
14/05	CorMedix Inc., Q1 2026 Earnings Call, May 14, 2026
14/05	CorMedix Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
14/05	Tranche Update on CorMedix Inc.'s Equity Buyback Plan announced on February 2, 2026.	CI
14/05	CorMedix: Q1 Earnings Snapshot	AQ
14/05	Cormedix Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update	AQ
14/05	CorMedix Therapeutics Raises Earnings Guidance for the Full-Year 2026	CI
05/05	CorMedix Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 14, 2026	AQ
28/04	RBC Raises Price Target on CorMedix to $14 From $13, Keeps Outperform, Speculative Risk	MT